๐ฌDeep Research
SUPN โ Supernus Pharmaceuticals ยท catalysts, narrative & risks
Supernus Pharmaceuticals (SUPN) โ Research Snapshot (as of 2026-10-27)
Context: Supernus is a mid-cap CNS-focused biopharmaceutical company (Nasdaq: SUPN), market cap ~$2.4B, trading near ~$40โ41, with a portfolio of eight marketed products and a late-stage pipeline. [18], [19] The dominant theme of the last quarter is the pending all-stock merger with Indivior, alongside an upcoming Q3 earnings print.
Recent Catalysts (last ~1โ3 months)
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ